Ontology highlight
ABSTRACT: Objective
We previously reported an increase in pneumothorax after implementing delivery room (DR) continuous positive airway pressure (CPAP) for labored breathing or persistent cyanosis in ≥35-week gestational age (GA) neonates unexposed to DR-positive pressure ventilation (DR-PPV). We hypothesized that pneumothorax would decrease after de-implementing DR-CPAP in those unexposed to DR-PPV or DR-O2 supplementation (DR-PPV/O2).Study design
In a retrospective cohort excluding DR-PPV the primary outcome was DR-CPAP-related pneumothorax (1st chest radiogram, 1st day of life). In a subgroup treated by the resuscitation team and admitted to the NICU, the primary outcome was DR-CPAP-associated pneumothorax (1st radiogram, no prior PPV) without DR-PPV/O2.Results
In the full cohort, occurrence of DR-CPAP-related pneumothorax decreased after the intervention (11.0% vs 6.0%, P < 0.001). In the subgroup, occurrence of DR-CPAP-associated pneumothorax decreased after the intervention (1.4% vs. 0.06%, P < 0.001).Conclusion
The occurrence of CPAP-associated pneumothorax decreased after avoiding DR-CPAP in ≥35-week GA neonates without DR-PPV/O2.
SUBMITTER: Stocks EF
PROVIDER: S-EPMC8853308 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature

Stocks Edward F EF Jaleel Mambarambath M Smithhart William W Burchfield Patti J PJ Thomas Anita A Mangona Kate Louise M KLM Kapadia Vishal V Wyckoff Myra M Kakkilaya Venkatakrishna V Brenan Shelby S Brown L Steven LS Clark Christopher C Nelson David B DB Brion Luc P LP
Journal of perinatology : official journal of the California Perinatal Association 20220216 6
<h4>Objective</h4>We previously reported an increase in pneumothorax after implementing delivery room (DR) continuous positive airway pressure (CPAP) for labored breathing or persistent cyanosis in ≥35-week gestational age (GA) neonates unexposed to DR-positive pressure ventilation (DR-PPV). We hypothesized that pneumothorax would decrease after de-implementing DR-CPAP in those unexposed to DR-PPV or DR-O<sub>2</sub> supplementation (DR-PPV/O<sub>2</sub>).<h4>Study design</h4>In a retrospective ...[more]